Bayer AG is talking its anti-bleeding drug Trasyol off the market following the release of a Canadian study that found it appears to be linked to higher risk of death than other drugs. The FDA asked Bayer to stop selling Trasylol pending further review of the Canadian study. The FDA approved Trasylol in 1993 and had previously recommended that Trasylol remain on the market despite studies linking it to various health problems.
The safety of Trasylol has been debated since a study published in January 2006 linked the drug to kidney damage, heart attacks and strokes. One of those studies previously was withheld by Bayer from the FDA due which Bayer attributed to a “regrettable human error.”
Trasylol is used to stop bleeding during heart bypass surgery by blocking enzymes that dissolve blood clots. The drug, which appears to be efficacious it is purpose, is designed to stop or slow blood loss, enabling patients receiving heart bypass surgery to avoid transfusions. Unfortunately, the risk of kidney damage, heart attacks and strokes appears to outweigh the salutary benefits Trasylol may have.
For the plaintiffs, the difficulty is going to be determining whether a heart bypass patient received Trasylol. Most bypass patients do not know the specific drugs given to them during surgery. So it most cases, you will need to request the necessary medical records to determine if Bayer’s drug was used.
If you have had a heart attack or a stroke after heart bypass surgery or if you have any questions, call our Trasylol lawyers at 1-800-553-8082 or click here for a free Internet consultation.